Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients

H Tedesco-Silva, Marcia Kho, A Hartmann, S Vitko, G Russ, L Rostaing, K Budde, JM Campistol, J Eris, I Krishnan, U Gopalakrishnan, J Klupp

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

Sotrastaurin, a novel selective protein-kinase-C inhibitor, inhibits early T cell activation via a calcineurin-independent pathway. Efficacy and safety of sotrastaurin in a calcineurin inhibitorfree regimen were evaluated in this two-stage Phase II study of de novo kidney transplant recipients. Stage 1 randomized 131 patients (2:1) to sotrastaurin 300mg or cyclosporine A (CsA). Stage 2 randomized 180 patients (1:1:1) to sotrastaurin 300 or 200mg or CsA. All patients received basiliximab, everolimus (EVR) and prednisone. Primary endpoint was composite efficacy failure rate of treated biopsy-proven acute rejection, graft loss, death or lost to follow-up. Main safety assessment was estimated glomerular filtration rate (eGFR) by MDRD-4 at Month 12. Composite efficacy failure rates at 12 months were higher in sotrastaurin arms (Stage 1: 16.5% and 10.9% for sotrastaurin 300mg and CsA; Stage 2: 27.2%, 34.5% and 19.4% for sotrastaurin 200mg, 300mg and CsA). eGFR was significantly better in sotrastaurin groups versus CsA at most time points, except at 12 months. Gastrointestinal and cardiac adverse events were more frequent with sotrastaurin. Higher treatment discontinuation, deaths and graft losses occurred with sotrastaurin 300mg. Sotrastaurin combined with EVR showed higher efficacy failure rates and some improvement in renal allograft function compared to a CsA-based therapy.
Original languageUndefined/Unknown
Pages (from-to)1757-1768
Number of pages12
JournalAmerican Journal of Transplantation
Volume13
Issue number7
DOIs
Publication statusPublished - 2013

Research programs

  • EMC MM-04-39-05

Cite this